MedTrace Logo

Use of Propranolol Hydrochloride in the Treatment of Metastatic STS

NCT03108300 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-02-23

No results posted yet for this study

Summary

Fifty patients with pathological proof of malignant soft tissue sarcoma will receive Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.

* The primary end point : To assess Progression Free Survival (PFS)
* The secondary end points : To assess Overall Survival (OS) and Toxicity Profile

Conditions

  • Malignant Soft Tissue Sarcoma

Interventions

DRUG

Propranolol Hydrochloride

propranolol hydrochloride is a beta-adrenergic receptor blocker

DRUG

Doxorubicin

Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-30
Primary Completion
2020-08-30
Completion
2021-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108300 on ClinicalTrials.gov